康莱特注射液联合CAF方案治疗乳腺癌的临床研究  

Clinical Observation of Kanglaite Injection Combined Chemotherapy in Treatment of Breast Cancer

作　　者：傅柏涵 李秋华[1,2] 韩涛[2] 郭放[2] 张静[2] 刘兆喆[2] 谢晓冬[2] 

机构地区：[1]辽宁中医药大学,沈阳110034 [2]沈阳军区总医院肿瘤科,沈阳110840

出　　处：《临床误诊误治》2015年第12期57-60,共4页Clinical Misdiagnosis & Mistherapy

基　　金：科技部十二五重大新药创制平台子课题(2012ZX-09303016-002);2012年辽宁省科技攻关计划课题(2012225019)

摘　　要：目的观察康莱特注射液联合CAF方案对乳腺癌的临床效果。方法选择2013年1月—2015年1月沈阳军区总医院肿瘤科收治住院的乳腺癌患者120例,按随机数字表法随机分为两组。对照组应用CAF方案化疗,治疗组在此基础上静脉滴注康莱特注射液200 ml/d,连用14 d为1周期。两组均化疗6疗程,化疗结束后评估并比较两组的临床效果、体力状况、生活质量、肿瘤标志物水平、化疗毒性及不良反应。结果治疗组体力状况改善情况、生活质量评估相关指标均明显优于对照组(P均<0.05)。治疗后两组癌胚抗原(CEA)、癌抗原153(CA153),与治疗前比较均显著降低(P<0.01),且治疗组降低程度优于对照组(P<0.01);治疗后两组均出现骨髓抑制,血红蛋白、白细胞及血小板计数与治疗前比较均降低(P<0.01),但治疗组降低幅度低于对照组(P<0.01)。治疗后治疗组症状评分下降明显,而对照组评分则增高,两组治疗后及组内与治疗前比较,差异均有统计学意义(P<0.01)。结论康莱特注射液联合化疗能改善患者化疗期间出现的临床症状,提高生活质量,降低化疗药物毒性及不良反应,效果可靠。Objective To observe clinical effect of Kanglaite injection combined with CAF chemotherapy in the treatment of breast cancer patients. Methods Clinical data of 120 breast cancer patients during January 2013 and January 2015 in our hospital were randomly divided into two groups; CAF chemotherapy control group,and the treatment group on the basis of intravenous KLT 200 ml / d,14 d / cycle. Both groups had six cycles of chemotherapy and were assessed for the clinical effects,physical condition,quality of life,tumor marker levels,toxicity and adverse reactions of chemotherapy. Results Physical condition of treatment group,related indexes of the quality of life assessment were significantly better than that of the control group（ P〈0. 05）. Carcinoembryonic antigen（ CEA） and Serum glycoprotein antigen 153（ CA153） of the two groups after treatment were significantly lower（ P〈0. 01）,and the extent of the treatment group was superior to that control group（ P〈0. 01）; after treatment,bone marrow suppression,hemoglobin,white blood cell and platelet counts of both the groups decreased compared with that before treatment（ P〈0. 01）,but a reduction in the treatment group rather than in the control group（ P〈0. 01）. After treatment,symptom score decreased significantly,while in the control group the score was higher,compared with that before treatment,and the differences were statistically significant（ P〈0. 01）. Conclusion Kanglaite injection combined with CAF chemotherapy can improve the clinical symptoms caused by chemotherapy,and improve quality of life,reduce cardiac toxicity,inhibit disease progression with reliable clinical efficacy.

关 键 词：乳腺肿瘤 药物疗法 联合 康莱特注射液 治疗结果 

分 类 号：R737.9[医药卫生—肿瘤]